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Abstract  19 
Cationic host defence peptides (CHDP), also known as antimicrobial peptides, are naturally-occurring 20 
peptides which can combat infections through their direct microbicidal properties and/or by influencing 21 
the host’s immune responses. The unique ability of CHDP to control infections as well as resolve 22 
harmful inflammation has generated interest in harnessing the properties of these peptides to develop 23 
new therapies for infectious diseases, chronic inflammatory disorders and wound healing. Various 24 
strategies have been employed to design synthetic optimized peptides, with negligible toxicity. Here, 25 
we focus on the progress made in understanding the scope of functions of CHDP and the emerging 26 








The global increase in multi-drug resistant pathogens along with a steady decline in the discovery of 2 
new antibiotics, underscores the need for new therapies to control infections. In addition, common 3 
treatments used for many chronic inflammatory diseases such as corticosteroids can increase 4 
susceptibility to infections1,2, including antibiotic recalcitrant pathogens3. There is therefore an urgent 5 
need for alternative strategies that can both kill pathogens as well as resolve harmful inflammation. 6 
One promising approach has emerged from the identification of Cationic Host Defence Peptides 7 
(CHDP), which can control infections either by their direct microbicidal properties and/or by 8 
modulating host immune responses, while also exhibiting the capacity to limit enhanced inflammation.  9 
 CHDP, also known as antimicrobial peptides, were first described in the 1960s by Kiss and Michl in 10 
the speckled frog4. Several seminal studies in the 1980s further defined antimicrobial peptides, notably 11 
cecropin isolated from moths by the Boman group5, defensins from human neutrophils by Ganz and 12 
Lehrer6, and magainins from amphibians by Zasloff et al7. CHDP are now known to be expressed 13 
across a diverse range of species, from microbes, plants, invertebrates to more complex amphibians and 14 
mammals.  15 
 CDHP are typically amphipathic small peptides with less than 50 amino acids and a net positive 16 
charge of +2 to +9 at physiological pH. However, these natural peptides differ significantly in sequence 17 
and structure, and are broadly classified into four structural groups based on conformation; α-helical 18 
linear peptides, those with β-sheet with disulphide bridges, cyclic peptides and peptides with extended 19 
flexible loop structures.  20 
 Initial research in the field was focused on the antimicrobial functions of this family of peptides, 21 
with a drive to discover new antibiotic-like therapies based on the naturally-occurring peptides. 22 
However, studies published in the 2000s established that the microbicidal action of some of these 23 
peptides e.g. the human cathelicidin LL-37 and β-defensins, were severely impaired under 24 
physiological salt concentrations (particularly by divalent cations) and in the presence of host factors 25 
such as anionic polysaccharides, apolipoproteins, DNA, f-actin and glycosaminoglycans8,9. The 26 
relatively poor direct microbicidal capabilities of these peptides under physiological conditions, at the 27 
low, naturally occurring concentrations observed in vivo, did not adequately explain their contribution 28 
in host defense against infections10,11. Subsequently, research over the last two decades has 29 
demonstrated that CHDP exhibit a wide range of functions beyond microbicidal activity, including the 30 
ability to influence immune responses, which contribute to their antimicrobial impact (reviewed in12-15). 31 
3 
 
This has led to the adoption of the current name for this family of peptides, Cationic Host Defence 1 
Peptides, which encompasses the wide range of described functions.  2 
 Over the last three decades there has been substantial interest in therapeutically harnessing CHDP, 3 
with more than 5000 papers published in this area of research since 2017 alone.  These include the 4 
examination of potential clinical uses for CHDP ranging from infections including multidrug-resistant 5 
bacteria16-19, to chronic inflammatory diseases such as arthritis20, asthma21 and colitis22, as well as some 6 
cancers23. Peptide-based therapeutics currently in clinical trials are primarily for the treatment of 7 
infections such as respiratory, oral and catheter-related infections, and for wound healing (see 8 
http://dramp.cpu-bioinfor.org/browse/ClinicalTrialsData.php).  9 
 This review will provide an overview of current understanding of the scope of functions of CHDP, 10 
primarily from eukaryotes.  Emerging therapeutic applications of these peptides, current clinical trials 11 
and the associated clinical developmental challenges will be discussed. Although there is increasing 12 
interest in the development of non-peptide mimics of CHDP for therapeutic application, such as 13 
peptoid analogs (reviewed in24), a comprehensive discussion of these approaches is beyond the scope 14 
of this review.  15 
 16 
[H1] Naturally occurring CHDP 17 
The antimicrobial peptide database has catalogued more than 2600 natural antimicrobial peptides, 18 
including those annotated as immunomodulatory25. The major families of CHDP from eukaryotes that 19 
are of interest from a drug discovery perspective are summarized below. 20 
 21 
[H2] Vertebrate CHDP  22 
CHDP from vertebrates have an essential role in the first line of defense against microbial pathogens. 23 
Upon infection, CHDP can kill pathogens through diverse mechanisms26-31 (discussed below), acting 24 
rapidly and directly on the pathogen when present in high local concentrations, or indirectly to modify 25 
components of host defense. These peptides exhibit immunomodulatory activities that can be either 26 
pro- or anti-inflammatory depending on the phase of the infection (see below)12-14,29. CHDP from 27 
vertebrates are amphipathic peptides containing amino acids with hydrophilic and hydrophobic side 28 
chains at opposite sides of the molecules. These CHDP can interact with the negatively charged 29 
membranes of bacteria. The two main classes of CHDP in vertebrates, the defensins and cathelicidins 30 
(Fig. 1a), are produced as prepropeptides which are cleaved to yield mature active peptides. 31 
4 
 
 Defensins have a common β-sheet core stabilized with three disulphide bridges between 6 conserved 1 
cysteine residues, and are subdivided into α-, β- and -defensins based on the linkage of cysteine 2 
residues. The genes encoding α- and β-defensins are adjacent on chromosome 8p23.1 and probably 3 
have common ancestry, with α-defensins thought to have evolved by gene duplication, and only found 4 
in some mammals, primarily primates and rodents32. Several of the human α-defensins are highly 5 
expressed in neutrophils, and other α-defensins are produced and secreted by Paneth cells in the small 6 
intestine6,33,34. The β-defensins are ubiquitous and present in all vertebrates. The human genome has 7 
>30 genes coding for β-defensins, and mice have even more genes coding for these peptides. These 8 
peptides are mainly produced in epithelial cells33,35. Finally, the cyclic -defensins arose from α-9 
defensins after the divergence of primates and have been purified from the leukocytes of rhesus 10 
macaques and baboons. These molecules are the only cyclic peptides found in mammals and exhibit 11 
antiviral activity. Thus varying between different species, evidence exists for sequence divergence by 12 
both positive and negative selection of mammalian defensin genes following ancestral gene 13 
duplication36-38. 14 
 Cathelicidins are produced as prepropeptides containing an N-terminal signal peptide, a cathelin-like 15 
domain, and the C-terminal mature peptide. The pro-cathelin-like domain is cleaved off primarily by 16 
serine proteases once the peptide is secreted39,40. These peptides are named after the conserved 17 
cathelin-like domain in the pro-peptide which is the common denominator of this family of peptides, as 18 
the active mature cathelicidins do not share sequence similarities. Most cathelicidins are α-helical (23-19 
37 amino acids), amphipathic, cationic peptides with a hydrophobic surface enabling interaction and 20 
perturbation of membranes with anionic surfaces. The only human cathelicidin LL-37 is the most well 21 
studied peptide in this family. LL-37 is an α-helical peptide and is one of several cleavage products of 22 
hCAP18, the product of the only human cathelicidin gene CAMP26. Other α-helical cathelicidins 23 
include the sole mouse cathelicidin CRAMP41 and chicken CATH-229. Another class of cathelicidins 24 
comprises β-hairpin peptides (12-18 residues) such as the bovine bactenecin that have one 25 
intramolecular disulphide bond. Cathelicidins such as protegrins (16-18 residues) have two 26 
intramolecular disulphide bonds and adopt β-sheet structures. Finally, linear cathelicidins (13-39 27 
residues) are enriched in specific amino acids e.g. tryptophan-enriched bovine indolicidin and proline-28 
rich porcine PR-39. Cathelicidins are immunomodulatory antimicrobials with an important role in the 29 
regulation of the inflammatory response29-31.  30 
 Several other vertebrate CHDP are also being explored as potential alternatives to antibiotics. 31 
Among these are histatins, which are histidine-rich CHDP constituents of saliva of mammals. Histatins 32 
5 
 
are less amphipathic than cathelicidins or defensins and may have different modes of action compared 1 
to other vertebrate CHDP as illustrated by their antifungal activity42. Finally, several CHDP produced 2 
by amphibian skin granular glands, such as magainin-2, have been used as prototypes for the 3 
development of novel antimicrobials43.  4 
 5 
[H2] Invertebrate, plant and fungal CHDP 6 
CHDP are a vital component of the innate immune system of all eukaryotic organisms, including 7 
plants, fungi and invertebrates which lack an adaptive immune system. These CHDP, similar to those 8 
from vertebrates, are also small amphipathic peptides with an overall positive net charge44,45. These 9 
peptides fall into several diverse and distinct structural groups, including α-helical peptides, β-sheet 10 
peptides, peptides with mixed α-helical and β-sheet structures, extended peptides and peptides enriched 11 
in specific amino acids (Fig. 1b). Their classification is generally dependent on the number, spacing 12 
and connectivity of cysteine residues as well as structure which is normally highly conserved within a 13 
CHDP family.  14 
 In plants, gene duplication and rapid evolution has produced large families of antimicrobial peptides 15 
within the same organism46. Genome sequencing has revealed that plants such as Arabidopsis and 16 
Medicago have up to 300 defensin or defensin-like sequences.  Apart from the cysteine residues and a 17 
glycine residue which are required for the defensin fold, these are highly diverse wherein the sequence 18 
diversity is displayed on the surface loops presented on conserved scaffolds. This may explain the 19 
diversity of biological functions defined for this family of proteins47. Plant defensins are generally 20 
potent antifungal molecules. However, plant defensins with antibacterial and insecticidal activity have 21 
also been described, along with those with roles in cell signalling, self- non-self-recognition during 22 
sexual reproduction, ion channel perturbation and enzyme inhibition46,47. Similar to the mammalian 23 
defensins, these also exhibit other functions, including roles in innate immunity, in addition to 24 
antimicrobial activity33,48. Although once considered an example of evolution of an ancient innate 25 
immunity molecule, it is now evident that mammalian and plant defensins evolved independently and 26 
are an excellent example of convergent evolution46.  27 
 28 
[H1] Synthetic peptides derived from CHDP  29 
The vast repertoire of sequences and structures of natural antimicrobial peptides allows for the design 30 
and development of novel therapeutic peptide analogues or peptidomimetics. Various approaches are 31 
being applied in the design of new drug candidates based on CHDP; such as single amino acid 32 
6 
 
substitution, using internal segments of CHDP to derive smaller peptides, as well as in silico methods 1 
to predict new synthetic peptides based on the understanding of structure-function relationships49-51. 2 
  3 
[H2] Synthetic innate defence regulator (IDR) peptides  4 
Early approaches to the development of CHDP as therapeutics focused heavily on optimizing the direct 5 
microbicidal properties of these peptides. However, it has become clear that strategies adopted to 6 
enhance in vitro microbicidal functions often resulted in peptides with increased levels of cytotoxicity. 7 
In addition, naturally occurring CHDP can also exhibit other functions undesirable for drug 8 
development such as an ability to induce mast cell degranulation, with release of histamine and 9 
prostaglandin, as well as activation of complement factors52,53.  Therefore, in the last decade, effective 10 
strategies have focused on designing synthetic peptides from sequences of CHDP to optimize 11 
antimicrobial functions in vivo, through a combination of some microbicidal activity along with 12 
beneficial immunomodulatory functions, in the absence of cytotoxic effects.  13 
Innate defence regulator (IDR) peptides are such small synthetic cationic peptides derived from 14 
natural CHDP, which have been screened and optimized for immunomodulatory functions12,54. 15 
Libraries of IDR peptides have been generated by screening overlapping fragments representing 16 
internal sequences of CHDP, and by single amino acid substitutions49-51. Most of the IDR peptides 17 
published to date are derivatives of the bovine CHDP bactenecin21,49,54. IDR peptides are non-18 
immunogenic and do not have the potentially adverse effects associated with some natural CHDP. In 19 
general, IDR peptides have a modest direct effect on the pathogen, yet can control infection in vivo and 20 
reduce inflammation, as shown in a variety of infection models54-56. The beneficial use of IDR peptides 21 
for the control of infections is now well established in preclinical models of a wide range of pathogens, 22 
including multidrug resistant bacteria, viruses, parasites, and antibiotic-recalcitrant bacterial 23 
biofilms54,56-60. IDR peptides also exhibit adjuvant functions to enhance mucosal immunity and 24 
antigen-specific humoral response61-64, and are effective in controlling inflammation and related 25 
physiological outcomes in models of sterile inflammation65 and chronic inflammatory diseases21. A 26 
distinct advantage of IDR peptide-based therapy, compared to current anti-inflammatory therapeutics, 27 
is the potential to resolve infections along with the ability to control inflammation54,57. 28 
 29 
[H2] Cryptic and synthetic peptides  30 
Several mammalian cationic proteins like histones, lactoferrin, thrombin and their cleavage products 31 
have antimicrobial activities. Histones and fragments thereof have a wide range of antimicrobial 32 
7 
 
activities66. These are not restricted to nucleosomes but are also found in the cytoplasm of cells and can 1 
be released upon activation. Indeed, up to 70% of the proteins of neutrophil extracellular traps (NETs) 2 
comprise histones and histone fragments67. Lactoferrin is another example of a protein that yields 3 
antimicrobial peptides upon proteolytic degradation in vivo. This protein is not confined to milk, it is 4 
produced by several tissues and has several biological activities related to host defense, including 5 
antimicrobial activity. Its proteolysis in the gastrointestinal tract produces fragments that are more 6 
active than the native protein68. Proteolytic digestion with pepsin releases lactoferricin, a peptide 7 
derived from the N-terminal region of lactoferrin. Other active fragments described are Lf(1-11) and 8 
lactoferrampin69. Similarly, synthetic molecules based on human -defensin pseudogenes, termed 9 
retrocyclins, have been developed as potential therapeutics for example as antivirals70. These 10 
observations that antimicrobial and/or immunomodulatory peptides can be released from larger 11 
proteins during inflammation or infection has led to the exciting concept of developing synthetic CHDP 12 
as prodrugs in which the N-terminus of the peptide is modified by a linker and a negatively charged 13 
promoiety. Such prodrugs can be selectively cleaved by a disease-associated enzyme, thereby targeting 14 
peptide activity to pathologically affected parts of the body71. In addition, these discoveries have led to 15 
bioinformatics approaches to identify segments of secreted proteins that could be developed as novel 16 
antimicrobial peptides of human origin. Bioinformatic tools have been developed to find those cryptic 17 
sequences and the peptides thus defined are known as cryptic peptides72. Among the identified and 18 
tested cryptic peptides are those from two apolipoproteins73. Other researchers have developed entirely 19 
novel antimicrobial peptides by high throughput screening of libraries of peptides that have been 20 
synthesized semi-randomly74,75 or by rational design51.  21 
 22 
[H1] Antimicrobial actions of CHDP 23 
The antimicrobial effects of CHDP on a wide range of pathogens have provided the impetus for the 24 
development of these peptides as broad-spectrum antimicrobials. Related mechanisms of action are 25 
diverse and appear to be dependent on the microbial pathogen.  26 
 27 
[H2] Antibacterial activity  28 
The bacterial membrane is the main target for most cationic peptides. Bacterial membranes are 29 
negatively charged because of the presence of anionic lipids, lipopolysaccharides (LPS; in Gram-30 
negative bacteria) or teichoic acids (in Gram-positive bacteria). These negatively charged molecules 31 
initiate an electrostatic interaction with cationic compounds which explains the preference of CHDP for 32 
8 
 
bacterial membranes compared to the membranes of cells from plants, invertebrates and vertebrates. 1 
The amphipathic nature of CHDP is important for the membrane-destabilizing properties of these 2 
peptides. CHDP can bind to the bacterial inner membrane leading to penetration of the peptide, leakage 3 
of bacterial cell contents and cell death27,28 (Fig. 2). In Gram-negative bacteria, interaction of CHDP 4 
with LPS results in perturbation of the outer membrane and this has been defined as a primary mode of 5 
action for the antimicrobial activity of CHDP76. Four main models of (inner) membrane perturbation 6 
have been proposed: aggregate, toroidal, barrel-stave and carpet model76 (Fig. 2). It should be 7 
cautioned that these proposed mechanisms of action stem largely from experiments with model 8 
membranes. As the interaction of CHDP with bacterial membranes does not involve a specific target, it 9 
has been speculated that the development of microbial resistance is unlikely.  Indeed, CHDP can elicit 10 
transient bacterial adaptations, the mechanisms of which are different from those involved in the 11 
development of bacterial resistance to conventional antibiotics. For example, a study has shown that 12 
removal of CHDP from the culture medium resulted in the bacteria reverting to their original state: the 13 
adaptation to counter the effect of the CHDP was not maintained77. Therefore, microbial ‘resistance’, 14 
as described for conventional antibiotics, is unlikely to develop for CHDPs.  15 
 In addition to inducing gross damage of bacterial membranes, CHDP may also affect cell wall 16 
synthesis. For example, defensins such as HNP-1 and hBD3 exert their antibacterial activity by docking 17 
on lipid II, the intermediate in peptidoglycan synthesis78-80. In addition, CHDP such as the ribosome-18 
binding proline-rich peptides can cross the bacterial membrane and kill bacteria from within, by 19 
binding to intracellular targets such as nucleic acids or nascent proteins and subsequently affect cell 20 
processes such as replication, transcription, translation, protein folding and cell wall synthesis28,76,81,82 21 
(Fig. 2). Simultaneous exposure of a pathogen to multiple different CHDP, potentially utilizing 22 
different modes of action, may be a critical mechanism by which these peptides are so effective in vivo. 23 
An exciting recent study in drosophila utilized CRISPR gene editing to delete all known immune-24 
inducible CHDP and demonstrated both additive and synergistic antimicrobial functions of the 25 
peptides, as well as highly specific CHDP-pathogen interactions in vivo83. 26 
 It should be noted that the antibacterial effects of CHDP are measured under non-physiological 27 
conditions in most in vitro studies. This is a problem as the direct microbicidal activities of many 28 
CHDP are antagonized under physiological in vivo conditions, such as higher ionic strength, presence 29 
of divalent cations and host lipids and proteins. Thus, it may be argued that CHDP may not function in 30 
vivo as antimicrobials with direct microbicidal properties11,84. However, some CHDP (and derived 31 
synthetic peptides) with compromised direct antimicrobial activity in vitro exhibit the capacity to 32 
9 
 
actively control infections in vivo, which may be due to local concentrations of CHDP released by 1 
neutrophil degranulation at the site of infection being higher than in vitro MIC values. A more 2 
plausible explanation is that CHDP-mediated immunomodulatory functions and/or the concerted action 3 
of CHDP with other immunity-related factors are critical in the resolution of infections in vivo 4 
(discussed below). However, the relationship between antibacterial potency of CHDP in vitro and its 5 
immunomodulatory functions is not understood. There is no evidence of an inverse correlation between 6 
antibacterial potency and the ability of CHDP to induce an immune response84. 7 
 8 
[H2] Antiviral Activity 9 
In addition to their antibacterial properties, early observations of the antiviral potential of CHDP85 have 10 
been expanded to demonstrate activity against a range of viruses. The majority of these studies in 11 
recent years have been performed in vitro and have described a variety of mechanisms that underpin 12 
the antiviral effects, differing in the context of specific viruses (Table I).  13 
 A common mechanism of action against many enveloped viruses (such as Influenza, Respiratory 14 
Syncytial virus, Zika, Vaccinia virus, and Kaposi's sarcoma-associated herpesvirus) in vitro is the 15 
capacity of CDHP (including defensins and cathelicidins) to destabilise the viral envelope upon 16 
contact, damaging the virions and inhibiting infectivity86-94. This may happen upon contact in solution 17 
or upon viral exposure to plasma membrane-associated CHDP during cell entry88. However, CHDP 18 
have also been shown to have antiviral activity against non-enveloped viruses (such as Rhinovirus, 19 
Human Papillomavirus 16 and Adenovirus), by decreasing viral replication95,96 and/or via binding viral 20 
capsid, thereby preventing uncoating and nuclear entry of the viral genome97-101. An additional 21 
mechanism of action against a number of viruses (such as Herpes Simplex Virus and HIV) relates to 22 
specific CHDP binding to cellular receptors involved in viral infection, that is dependent upon the 23 
lectin-like properties of some peptides102-110. Further antiviral effects may also result from CHDP-24 
mediated aggregation of viral particles111, inhibition of PKC activity112,113, and immunomodulatory 25 
effects (discussed in detail below) of the peptides on host immune cells such as enhancing phagocyte 26 
function111,114 or by modification of cytokine responses115,116. These antiviral mechanisms highlight the 27 
possibility that baseline expression of CHDP could create an “antiviral shield” at mucosal surfaces and 28 
prevent replication and spread of virus, if upregulated after initial infection. Therapies aimed at 29 
inducing host CHDP expression, or the application of synthetic CHDP-derived peptides with defined, 30 




[H2] Antifungal activity 1 
Fungal infections in humans are a growing problem world-wide. Many patients suffer from non-life-2 
threatening fungal infections of the skin and oral cavity. However, invasive infections by fungal species 3 
such as Aspergillus fumigatus, Cryptococcus neoformans, Candida albicans and Histoplasma 4 
capsulatum are responsible for the death of 1.5 million people annually117. Only a limited set of 5 
antifungals is available for the treatment of life-threatening fungal infections and the development of 6 
antifungal drug resistance continues to increase118. This is particularly evident for azole-resistance 7 
because of the wide-spread use of azoles in agriculture119. In addition, the world-wide number of 8 
immunocompromised patients is increasing which leads to more fungal infections. Both trends are very 9 
disturbing and demand the development of new potent antifungals that do not easily elicit resistance. 10 
Furthermore, it is important that novel antifungal compounds be only used in humans to prevent rapid 11 
resistance development in the environment. Because of their diverse modes of action CHDP-derived 12 
molecules may be used as paradigms for the development of potent antifungals. Antifungal CHDP 13 
from plants and vertebrates have been described48. The activity of plant defensins has primarily been 14 
described against fungi120. Various killing mechanisms of CHDP on yeast and fungi have been 15 
reported, ranging from effects on mitochondrial functions of Candida albicans by histatin 5 to 16 
membrane effects on this yeast by cathelicidins and CHDP mimics121-123. It should be noted that fungal 17 
biofilms are highly resistant to antifungals124. It is thus important to screen for the anti-biofilm activity 18 
of newly developed CHDP-based antifungals124. 19 
 20 
[H1] Immunomodulatory actions of CHDP  21 
The earliest studies into the non-microbicidal properties of CHDP were on their effects on immune 22 
cells, primarily related to the ability of these peptides to recruit leukocytes125-127. Following this, 23 
research on immunity-related functions of CHDP increased exponentially over the next two decades, 24 
defining a diverse range of functions. Immunity-related functions of CHDP seem to be dependent on 25 
the environmental stimuli, cell and tissue type, interaction with different cellular receptors, and the 26 
concentration of the peptides. Studies to date indicate that the molecular mechanism underpinning the 27 
ability of CHDP to selectively modulate immune responses is highly complex involving intracellular 28 
uptake of the peptides, which may or may not be mediated by membrane-associated GPCR, interaction 29 
with several intracellular interacting protein partners or receptors (e.g. GAPDH and p62), alteration of 30 
several signaling pathways (NFκB, p38 and JNK MAPK, MKP-1, and PI3K), engagement of different 31 
transcription factors, all of which seem to be dependent on factors such as the peptide concentration, 32 
11 
 
kinetic of response and the environmental stimuli (reviewed in12,15,128,129). The pleiotropic 1 
immunomodulatory functions of CHDP raise questions regarding the primary biological role of these 2 
peptides. Below, we summarize the activities of CHDP on modulation of immunity and inflammation 3 
(Fig. 3), primarily focusing on cathelicidins and defensins. Understanding mechanisms that underpin 4 
the ability of CHDP to modulate immunity to protect against infection, resolve inflammation and 5 
contribute to immune homeostasis, is critical to the development of novel therapeutic approaches based 6 
on CHDP-derived peptides. 7 
 8 
[H2] Immune activation 9 
Protective activation of the innate immune system by CHDP has emerged as one of the key 10 
mechanisms underpinning the ability of these peptides to promote early clearance of infections. The 11 
actions of CHDP include recruiting leukocytes, modulating neutrophil responses and influencing 12 
antigen-specific adaptive immunity (discussed below). In addition, the interaction of CHDP and the 13 
microbiome in mucosal immunity is a rapidly emerging area of research. Although beyond the scope of 14 
this review, this exciting area of research suggests the potential for CHDP-mediated selectivity in 15 
control of the microbiome130-133, but also the potential for components of the microbiome to contribute 16 
to the regulation of CHDP expression. Further research on CHDP-microbiome interaction may enhance 17 
understanding of the consequences of microbial dysbiosis in disease states, aging and following 18 
treatment with broad-spectrum antibiotics.  19 
 20 
[H3] Leukocyte recruitment  21 
Immune cells e.g. neutrophils, macrophages, mast cells and T-cells exhibit direct chemotactic activity 22 
towards CHDP and their IDR derivatives54,57,127,134-136. CHDP also indirectly promote recruitment of 23 
leukocytes by inducing the release of chemokines10,128,137-140. The ability of these peptides to induce 24 
chemokine release and enhance recruitment of leukocytes has been defined as a primary 25 
immunomodulatory mechanism related to their ability to protect against infections54,57,141. Underlying 26 
mechanisms involve several cellular receptors such as chemokine receptors (e.g. CCR6 and CCR2), G-27 
protein coupled receptors (GPCR) including the formyl peptide receptors (reviewed in 12,142), and Toll-28 
like receptors (TLR)135,143,144, as well as interaction with intracellular proteins such as GAPDH and 29 
p62145,146. However, these functions appear to be dependent on the phase of infection and 30 
inflammation, as it has been shown that LL-37 can mediate the internalization of chemokine receptor 31 
CXCR2 on monocytes and neutrophils, consequently dampening chemotaxis147. Molecular processes 32 
12 
 
that control the dichotomy of CHDP to selectively induce chemokine secretion and enhance leukocyte 1 
recruitment, without altering the anti-inflammatory functions of the peptide (discussed in the next 2 
section) are not completely understood.  3 
 4 
[H3] Neutrophil function 5 
Neutrophils are the major innate immune effector cells of the early phase response to infections, and 6 
are a primary source of both defensins and cathelicidins which are stored pre-formed in the secondary 7 
and primary granules respectively, and released upon neutrophil degranulation. CHDP can influence 8 
the function of neutrophils to modify infection outcomes. For example, these peptides can enhance 9 
influx of neutrophils both by direct chemotactic function127,136,144 and indirectly by promoting the 10 
secretion of neutrophil chemokines e.g. IL-8 and Gro-α in a MAPK-dependent manner137,148, to 11 
promote control of infections. Similarly, a recent study has shown that CHDP hepcidin induced in the 12 
skin during bacterial infections can enhance chemokine production and promote neutrophil 13 
responses149. CHDP are also located on neutrophil NETs, potentially contributing to NET-mediated 14 
antibacterial effects150. LL-37 can facilitate NET formation and contribute to antiviral activity, as 15 
reported for influenza A virus86. It should be noted that recent studies have shown that post-16 
translational modifications of CHDP, in particular citrullination, may alter the functions of NET 17 
associated CHDP such as cathelicidins151-153. LL-37 can also promote bacterial clearance in vivo by 18 
enhancing early neutrophil responses154. In addition, LL-37 can induce intracellular calcium 19 
mobilisation and the generation of reactive oxygen species (ROS)147 as well as enhance ROS 20 
production mediated by other inflammatory stimuli155, indicating the capacity to prime and enhance 21 
neutrophil antimicrobial functions. The ability of CHDP to modulate the host cellular response to 22 
infections is not restricted to effects on neutrophils, these peptides can also modify other innate and 23 
adaptive cellular responses (reviewed in12,14,29,33).  24 
 25 
[H3] Antigen presentation and adaptive immunity  26 
CHDP serve as a link between innate and adaptive immunity, as a consequence of their capacity to 27 
recruit antigen presenting cells (APCs) such as monocytes / macrophages and dendritic cells (DCs) to 28 
the site of infections (as discussed above). These peptides can also enhance phagocytosis in 29 
macrophages, facilitating clearance of bacteria by boosting immune activation156-159. CHDP can not 30 
only activate APCs, but also influence the generation and polarization of lymphocyte responses, thus 31 
shaping the adaptive immune response. For example, human defensins hBD2 and hBD3 can both 32 
13 
 
induce production of IFN-α from plasmacytoid DCs and consequently influence the initiation of T-cell 1 
responses160. The expression of co-stimulatory molecules CD80, CD86 and CD40 on myeloid cells are 2 
also upregulated by exposure to hBD3, facilitating the promotion of adaptive immune response via the 3 
engagement of TLRs161. LL-37 can modulate the adaptive immune response by multiple effector 4 
functions; LL-37 facilitates enhanced expression of co-stimulatory molecules and promotion of a 5 
modified adaptive response via modulation of dendritic cell differentiation and function in vitro159,162 6 
and in vivo163, promotes DC activation164,165 and enhances the activation/ proliferation of B-cells via 7 
activating follicular DCs166. The influence of CHDP on adaptive immunity has led to the examination 8 
of application of these peptides, primarily cathelicidins, as adjuvants to enhance systemic and mucosal 9 
antigen-specific immune responses144,160,166. 10 
 11 
[H2] Regulation of inflammation 12 
As discussed above, CHDP exhibit multiple functions to activate the immune system which can be 13 
classified as pro-inflammatory responses that aid in the clearance of pathogens. In contrast, potent 14 
CHDP-mediated anti-inflammatory effects have been demonstrated in the presence of an inflammatory 15 
and/or pathogenic challenge, thus suggesting that CHDP are also regulatory molecules that limit 16 
enhanced inflammation. Therefore, rather than being described as either pro- or anti-inflammatory 17 
molecules, it may be appropriate to define CHDP as molecules that can balance inflammation to 18 
promote immune homeostasis. The anti-inflammatory function of CHDP is reinforced by several 19 
studies that have demonstrated that the deficiency of these peptides results in increased inflammatory 20 
responses; cathelicidin-deficient mice exhibit a more severe inflammatory phenotype compared to wild 21 
type155,167,168. Similarly, reduced expression of β-defensin in enterocytes of humans has been associated 22 
with Crohn’s disease169. Indeed the critical role of defensins in maintaining the integrity of intestinal 23 
mucosa and immune homeostasis is well established (reviewed in34). Notably, exogenous application of 24 
CHDP e.g. LL-37, CATH-2 and BMAP-28, hBD2, and synthetic peptides e.g. IDR-1 and IDR-1002, 25 
has been shown to control inflammation in various animal models of infections and sepsis55,57,59,60,170-26 
173. Similarly, an LL-37-derived peptide controlled the disease process in a murine model of 27 
inflammatory arthritis20, and IDR-1002 effectively alleviated airway inflammation in vivo21. In 28 
contrast, cathelicidin-KO mice demonstrate increased survival rate in a cecal ligation and puncture 29 
model of sepsis, despite increased expression of pro-inflammatory genes167. Therefore, the outcome of 30 
CHDP-mediated immunomodulatory responses seems to be context dependent and reliant on the 31 
14 
 
cellular environment. This has been demonstrated in studies examining the cross talk between TLR and 1 
CHDP, as discussed below. 2 
 3 
[H3] Crosstalk of CHDP with TLRs 4 
Several studies have demonstrated that cathelicidins exhibit potent anti-endotoxin properties in vitro 5 
and in vivo10,138,170,174,175, both by binding bacterial lipopolysaccharide (LPS)174,175 and by intervening 6 
in TLR signaling mechanisms138. The ability of cathelicidins such as LL-37 to modulate TLR-to-NFκB 7 
signaling is not restricted to its effect on TLR4, as LL-37 also dampens responses to TLR2/1 agonists 8 
and whole bacteria10,176. Downstream outcomes of CHDP-mediated modulation of the TLR-to-NFκB 9 
pathway in the presence of inflammatory stimuli results in the selective suppression of specific pro-10 
inflammatory responses such as production of TNF and ROS, without the neutralization of innate 11 
immune functions such as chemokine production, and concurrent enhancement of anti-inflammatory 12 
mediators such as IL-10, IL-1RA, A20 and NFκBIA138,177-180. A caveat is that the effect of endogenous 13 
CHDP to limit inflammation may be impeded by peptide modifications that occur under inflammatory 14 
conditions. A recent study demonstrated that the enzyme peptidyl arginine deaminase released by 15 
inflammatory cells can mediate citrullination of LL-37, which compromises the ability of the peptide to 16 
intervene in TLR-signaling to dampen pro-inflammatory responses in macrophages, and to control 17 
sepsis in vivo151. Therefore, it is essential to consider the composition of the inflammatory milieu in 18 
studies that aim to define or optimize the anti-inflammatory functions of cationic peptides. 19 
 It should be noted that the modulation of TLR-mediated signalling by CHDP is not necessarily 20 
“anti-inflammatory”, as these peptides can also induce chemokines to attract leukocytes such as IL-8 21 
and MCP-1 (pro-inflammatory response) at the same time as inhibiting LPS-induced TNF10,138,181. 22 
Similarly, cathelicidins can also exhibit both pro- or anti-inflammatory activities depending on the 23 
phase of the infection. For example, CATH-2 enhances the sensing of bacterial DNA182 and is not anti-24 
inflammatory if the bacterial infection has not been completely resolved182,183, while LL-37 promotes 25 
acute protective pro-inflammatory responses primarily in the context of an infection, including via 26 
activation of the inflammasome, but not in the absence of pathogens154,184. However, in instances where 27 
the bacteria are killed, both LL-37 and CATH-2 exhibit anti-inflammatory activity and can prevent 28 
activation via TLR2 and TLR4183. This is one of the mechanisms described for cathelicidin-mediated 29 
dampening of inflammatory responses induced by bacterial products, which may be especially 30 
important in pulmonary infections to protect the respiratory epithelium173.  31 
15 
 
 Similarly, human defensins e.g. hBD3 exhibit anti-endotoxic properties in vitro and in vivo, via 1 
modulation of TLR signalling pathways185,186, but also induces the production of pro-inflammatory 2 
cytokines by monocytes161, increases TLR9-dependent responses to bacterial DNA187, and modifies 3 
MDA- and TLR-mediated responses to Poly I:C188. In addition, hBD3 can induce the maturation of 4 
dendritic cells (DC)161, while hBD2 and 3 can induce TLR9-dependent plasmacytoid DC IFN-α 5 
release, secondary to interaction between the peptides and otherwise non-inflammatory DNA to 6 
mediate in vivo adjuvant properties189. This is similar to the capacity to mediate TLR7-, TLR8- and 7 
TLR9-dependent immunogenic responses to self-DNA/RNA, which was first described for LL-8 
37164,165,190. However, LL-37 enhances TLR3-mediated responses191,192 and promotes release of IL-9 
1β193. These observations demonstrate the potential of CHDP to modulate innate and downstream 10 
adaptive response via their impact upon pattern recognition signalling pathways.  11 
 12 
[H3] Modulation of cytokine-mediated responses 13 
Limited studies have demonstrated the ability of CHDP, especially LL-37, to modulate cytokine-14 
mediated responses in various cell types. LL-37 induces the expression of the IL-1 family of genes 15 
including Th17/Th1-related genes such as IL-6 and IL23A in keratinocytes194. Consistent with this, 16 
another study demonstrated that LL-37 can synergize with cytokines IL-1β and GM-CSF to enhance 17 
chemokine production, but not with cytokines such as IL-4 or IL-12, in human PBMC195. In contrast, 18 
LL-37 suppresses cytokine IL-32-induced pro-inflammatory cytokines such as TNF, IL-6 and IL-1β, 19 
by activating the dual phosphatase MKP-1 which is a known negative regulator of inflammation, 20 
without altering its ability to induce chemokine production177. Mechanisms that control the ability of 21 
CHDP such as LL-37 to limit inflammation without altering chemokine production are not completely 22 
understood. To that end, a recent study has demonstrated that LL-37-induced chemokine release and 23 
subsequent leukocyte recruitment is selectively mediated by GPCR via the CdC42 RhoGTPase 24 
pathway, without impacting LL-37-induced anti-inflammatory cytokine release137.  25 
 26 
[H2] Cell death  27 
Although CHDP can rapidly permeabilize prokaryotic membranes, most natural peptides are relatively 28 
less toxic to eukaryotic cells. CHDP such as LL-37 and CATH-2 can enter eukaryotic cells182,196 and 29 
facilitate the entry of nucleic acids and DNA dyes182,193,197, without inducing cell lysis, suggesting a 30 
temporary membrane disruption or pore opening. However, exposure to high concentrations of LL-37 31 
induces eukaryotic cell apoptosis in vitro and in vivo 198-201. This phenomenon is cell type-dependent 32 
16 
 
with the viability of primary human lymphocytes and monocytes relatively unaffected by exposure to 1 
high concentrations of the peptide159,202. The impact of CHDP-mediated induction of apoptosis on 2 
innate or adaptive responses in vivo remains unknown. However, high concentrations of LL-37 have 3 
been found to preferentially induce death in infected epithelial cells and represent a potential additional 4 
host defence mechanism184,199. Furthermore, different modes of cell death have important roles in 5 
maintaining immune homeostasis, and in amplifying or dampening, and later resolving, inflammatory 6 
responses. In this context, the control of neutrophil death and anti-inflammatory properties of apoptotic 7 
neutrophils is particularly important203. Interestingly, LL-37 can induce rapid secondary necrosis of 8 
apoptotic neutrophils178,204, with anti-inflammatory effects upon activated macrophages being 9 
associated with LL-37-mediated release of granule contents from the apoptotic cells, perhaps resulting 10 
from release of LL-37 and -defensins from these apoptotic neutrophils205. Thus, CHDP-mediated 11 
regulation of cell death has the potential to affect the magnitude and the resolution of inflammatory 12 
responses to infection.  13 
 14 
[H1] Development of CHDP-based therapies 15 
Based on the properties discussed above, many CHDP from either prokaryotes or eukaryotes and their 16 
derivatives are currently being investigated for a variety of indications including their use as 17 
antimicrobials and anti-inflammatories, as well as their application in wound healing,  18 
 19 
[H2] Antimicrobial therapies  20 
[H3] Preclinical studies 21 
Studies in murine models have demonstrated the critical role of CHDP in the control of infections. For 22 
example, cathelicidin-deficient mice206 exhibit less effective host defense against Streptococcal skin 23 
infections206, impaired clearance of Pseudomonas aeruginosa infections from the lung207 and the 24 
cornea208, develop more severe pox skin lesions upon infection with Vaccinia virus92, develop more 25 
severe infection with RSV upon challenge90, and exhibit increased susceptibility to infection with 26 
Citrobacter rodentium in the intestinal tract209, Escherichia coli in the urinary tract210 and Klebsiella 27 
pneumoniae in the lung211. The impaired antimicrobial activities observed in these cathelicidin-28 
deficient mice may be explained by the absence of direct effects of the mouse cathelicidin, CRAMP, on 29 
these pathogens, although the observed effects may also be the result of altered immune modulation in 30 
the knock-out mice.  31 
17 
 
Exogenous administration of many CHDP has been found to be effective in various animal infection 1 
models for bacterial, viral, and fungal infections (reviewed in12,212).  However, it remains to be 2 
determined if the observed efficacy is primarily due to the direct antimicrobial activities of the 3 
administered CHDP on the pathogen or due to the effect of the peptides on host immunity, or a 4 
combination of both. Therefore, the mode of action of the peptides needs to be carefully examined in 5 
vivo.    6 
 Several factors have limited the success of oral or systemic use of CHDP in preclinical studies, 7 
including (i) high local concentrations of CHDP, (ii) concerted actions of different CHDP and (iii) 8 
synergism with other molecules at the site of infection. However, many in vivo studies have shown 9 
efficacy of CHDP-derived peptides when these are administered topically. For example, a recent study 10 
showed that topical application of a peptide designed using LL-37 and Tachyplesin 1 as chemical 11 
benchmarks was protective in a MRSA murine model213. Similarly, localized intra-tracheal 12 
administration of a CHDP-derived peptide was shown to be better in lowering bacterial load in the 13 
lungs compared to rifampicin treatment in a murine model of tuberculosis214. Moreover, nanostructure-14 
based technology has recently shown promise as an effective delivery system for slow release of 15 
peptides for infection control in vivo215. 16 
A growing area of interest is the potential use of CHDP with indwelling medical devices, prosthetic 17 
joints and other implants for the prevention of nosocomial infections216,217. Bacterial biofilm formation 18 
on medical devices include pathogens recalcitrant to antibiotics which results in biomaterial-associated 19 
infections, a major problem in clinical practice. CHDP may be immobilized on the surfaces of 20 
biomaterials to prevent adhesion of bacteria. For example, synthetic peptides designed from LL-37 and 21 
a trombocidin-derived peptide was shown to be effective in inhibiting biofilm formation by a 22 
biomaterial-associated clinical isolate of S. aureus216.  In addition, depending on the chemical tethering 23 
procedure, it is possible to retain antibacterial activity of CHDP after coating the surface. The 24 
disadvantage of this approach is that only bacteria in the immediate vicinity of the surface are killed. 25 
Application of CHDP-releasing biomaterials may be a better approach to prevent infections from 26 
implants. It has been reported that several hydrogels and also nanotubes and microporous calcium 27 
phosphate coatings inhibit bacterial growth in vivo217.  28 
 Another potential application of CHDP is their development as potential first line antiviral 29 
treatments for use during pandemics, where there is insufficient time to produce vaccines (such as new 30 
influenza (IAV) pandemics), or for viral infections for which vaccines are not available (such as 31 
Respiratory Syncytial Virus (RSV)), and more broadly for other viral pathogens. An early proof of 32 
18 
 
concept study in mice demonstrated that gel-based application of HD5 protected against HSV 1 
infection102. More recently, intravaginal instillation of a synthetic defensin, identified by HD5 mutant 2 
screening, showed prophylactic and/or therapeutic efficacy in a lethal HSV-2 infection model103. In 3 
another example, prophylactic application of RC-2 in a murine HSV-mediated ocular keratitis model 4 
modestly reduced viral titres and reduced disease105, but had no effect on disease pathology when 5 
applied post-infection. Intranasal human and murine cathelicidins both have shown in vivo antiviral 6 
activity equivalent to current first line neuraminidase inhibitors in a lethal murine IAV model, when 7 
applied concomitantly with virus and daily thereafter, dramatically improving survival despite modest 8 
effects on viral load116. Similarly, intranasal Urumin87, intranasal mBD2 (optimal when premixed with 9 
virus before infection218), intravenous delivery of recombinant mBD3219 or intramuscular delivery of 10 
mBD1-mBD3 fusion genes220 were all protective in murine lethal IAV infection models. These studies 11 
all demonstrate the therapeutic potential of CHDP as antivirals in vivo, although further investigation is 12 
needed. Many in vivo studies suggest that while early direct contact of virus and CHDP may be 13 
protective due to direct damage to the virions, later stage modulation of host immune / inflammatory 14 
responses by the peptides may also be critical in the antiviral activity of a CHDP115,221. Such 15 
observations highlight the importance of studies that address both the direct microbicidal activities and 16 
the immunomodulatory properties of these peptides.  17 
 18 
[H3] Clinical trials 19 
Most CHDP in clinical trials so far have been formulated for topical applications or as inhalants for the 20 
treatment of infections (see http://dramp.cpu-bioinfor.org/browse/ClinicalTrialsData.php and Table 21 
II222). One of the most advanced of these was Pexiganan, an analogue of the magainin peptide, which 22 
was tested as a topical cream for the treatment of infected diabetic foot ulcers in Phase III clinical trials. 23 
However, development was terminated because it did not perform better than current treatments. There 24 
are several trials in progress using Omiganan, a CHDP-derived antimicrobial compound (detailed in 25 
Table II). For example, a Phase III trial evaluating the long-term safety for topical application of 26 
Omiganan as a treatment for rosacea is ongoing. In addition, localized application of a human 27 
lactoferricin-derived peptide PXL01-containing hydrogel was shown to be safe, well tolerated and 28 
effective as anti-adhesion treatment postoperatively after tendon repair surgery, in an in-patient Phase 29 
II clinical trial223. Also, clinical trials are ongoing for topical application of LL-37 for treatment of 30 
venous leg ulcers (Table II)224.  31 
19 
 
A small number of clinical trials investigating the toxicity and efficacy of CHDP using oral and 1 
intravenous administration routes have also been conducted or are ongoing (Table II). For example, 2 
Iseganan, an analog of the peptide protegrin was used as an oral solution for oral mucositis in Phase III 3 
clinical trial, but did not show significant efficacy (Table II). Similarly, Surotomycin and Isegan 4 
completed Phase III trials but were rejected for ongoing development either due to poor efficacy or 5 
efficacy that was not superior to current drugs (Table II). Phase III clinical studies using intravenous 6 
Brilacidin, a synthetic defensin mimetic), for skin infections are starting soon. Recently, Phase III trials 7 
of Murepavadin as an intravenous treatment for bacterial pneumonia were terminated due to increased 8 
serum creatinine levels in patients, indicative of acute kidney injury. This is reminiscent of 9 
nephrotoxicity issues with polymyxins, the cationic nonribosomal peptides which were used for 10 
treatment of Gram-negative bacterial infections and are currently used as the antibiotics of last resort.  11 
Another strategy being evaluated and tested in clinical trials is to enhance the 12 
expression/production of endogenous CHDP for chronic inflammatory and infectious disease. A 13 
multicentre, double-blind, randomized clinical trial demonstrated that supplementation with vitamin D 14 
was beneficial to control exacerbations in COPD, especially for patients deficient in vitamin D225. 15 
Vitamin D3 results in the induction of LL-37 in macrophages which has been also associated with 16 
intracellular killing of Mycobacterium tuberculosis in a human trial226. Similarly, oral phenylbutyrate, 17 
with or without vitamin D supplementation, leads to the induction of LL-37 in macrophages and 18 
lymphocytes, and has been evaluated in the treatment of adults with active pulmonary tuberculosis226. 19 
Therefore, strategies to enhance endogenous CHDP production may be valuable for antimicrobial 20 
therapies to counter challenges associated with peptide delivery, stability and bioavailability.  21 
 In summary, only a handful of peptide-derived treatments have made it to market, they include 22 
PAC-113, a histatin analog that is being sold in Taiwan as a topical treatment for oral candidiasis and 23 
Dalbavancin, a semisynthetic lipoglycopeptide that has been approved in the US for intravenous 24 
treatment of acute skin infections.  Although the failure rate has so far been high, the number of CHDP 25 
in clinical trials has grown rapidly and is likely to lead to success in the future. 26 
 27 
[H2] Immunomodulatory therapies  28 
[H3] Preclinical studies 29 
Early clinical trials using synthetic analogues of CHDP that had been designed to maximize 30 
microbicidal activity achieved only moderate efficacy227, perhaps due to failure to recognize the 31 
importance of immunity-related functions of these peptides. Despite issues of concentration at mucosal 32 
20 
 
surfaces and antagonizing factors at sites of inflammation, CHDP are clearly essential for the control of 1 
infections in vivo90,92,206-211. Application of LL-37 is protective against infection with P. aeruginosa, 2 
influenza and RSV in vivo 89,116,228, with mode of action involving enhanced, protective early neutrophil 3 
responses, rather than by direct microbicidal activity against the pathogen154. Comparable results were 4 
also obtained after in ovo application of CATH-2 in chickens to induce a long-lasting protection against 5 
respiratory E. coli infections229. Similarly, CHDP-derived synthetic peptides such as IDR peptides were 6 
also shown to be protective in various infection models wherein IDR peptides protect the host from the 7 
pathogen by modulating the host immune response, and in parallel suppress the release of 8 
inflammatory cytokines such as TNF and IL-6, suppress reactive oxygen species (ROS), and dampen 9 
neutrophil degranulation54,57-59. These studies demonstrate that CHDP or related synthetic peptides can 10 
provide protection against infections by modulating host immune response rather than by directly 11 
targeting the pathogen.  12 
Synthetic IDR peptides are primarily being developed as immunomodulatory therapies to control 13 
infections, with particular focus on antibiotic resistant infections. IDR-1 was the first such peptide 14 
shown to be protective against both Gram-positive and Gram-negative bacteria, including antibiotic-15 
resistant infections such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-16 
resistant Enterococcus (VRE) and Salmonella in murine preclinical models54. Subsequently, an analog 17 
of IDR-1, peptide SGX94, showed broad-spectrum activity against bacterial infections solely by 18 
modulating the host immune response to control infections in pre-clinical studies230. Other IDR 19 
peptides such as IDR-1002 and IDR-1018 have also been shown to be beneficial in preclinical models 20 
of a wide range of pathogens, including multidrug resistant bacteria, viruses, parasites, and antibiotic-21 
recalcitrant bacterial biofilms56-59. In general, the mechanism of action of IDR peptides is primarily 22 
mediated by influencing host innate immune responses to enhance immune cell recruitment to the site 23 
of infection to promote bacterial clearance, rather than by directly targeting the pathogen. IDR peptides 24 
also influence neutrophil functions to augment neutrophil-mediated killing of bacteria and the release 25 
of natural CHDP from neutrophils231.  26 
In addition to the potential application of CDHPs in infections, the immunomodulatory functions of 27 
these peptides are being examined for use in other indications. Cathelicidin-deficient mice develop 28 
more severe colitis in a non-infectious DSS-induced model with greater pro-inflammatory cytokine 29 
expression and cell death compared to wild type controls, and with impaired mucus production232. In 30 
contrast, therapeutic intrarectal administration of the murine cathelicidin mCRAMP (or mCRAMP-31 
expressing Lactococcus lactis) is protective in the DSS-induced colitis murine model233,234. Similarly, 32 
21 
 
therapeutic administration of exogenous LL-37 or mCRAMP can modulate C. difficile colitis by 1 
inhibiting toxin-A-associated intestinal inflammation235. These studies suggest that CHDP and/or 2 
derived synthetic peptides have the potential to control chronic inflammatory diseases. Consistent with 3 
this, limited preclinical studies have demonstrated the beneficial effects of CHDP-derived synthetic 4 
peptides for chronic inflammatory diseases such as in inflammatory arthritis20, asthma21, and in colitis22 5 
models. For example, exogenous administration of a LL-37-derived synthetic peptide prevented the 6 
development of arthritis, suppressed autoantibodies and prevented cartilage degradation of the joints, in 7 
a collagen-induced arthritis murine model20. Elafin delivered by adenovirus ameliorated colitis, 8 
suppressed inflammatory cytokines and related NF-κB activation in non-infectious DSS-induced colitis 9 
murine model22. In addition, the peptide IDR-1002, a bactenecin derivative, improved allergen-induced 10 
airway hyperresponsiveness, controlled airway inflammation and suppressed inflammatory cytokine 11 
IL-33 production, in a murine model of asthma21. These preclinical studies suggest that CHDP and 12 
their derivative peptides can be developed for non-infectious inflammatory diseases.  13 
Due to the ability of CHDP to regulate inflammation, many studies have also explored the effects of 14 
these peptides on cancers. However, the therapeutic use of CHDP-based peptides for cancers remains 15 
controversial, as the effect of these peptides on cancer pathology seems to be dependent on the specific 16 
type of cancer236. Discussing the nuances of pharmaceutical relevance of CHDP in cancer pathology is 17 
beyond the scope of this review237,238. Nevertheless, a gene therapy study using hDB2 showed that 18 
application of this peptide resulted in enhanced local anti-tumor effects in preclinical murine models 19 
using CT26, MethA and LL/2 tumor cells, the mechanism of which was associated with 20 
immunomodulatory functions of the peptide, namely its ability to activate endogenous dendritic cells23.  21 
Another promising avenue for harnessing the immunomodulatory functions of IDR peptides is their 22 
application as adjuvants for new vaccine formulations, as IDR peptides enhance mucosal immunity and 23 
antigen-specific humoral responses61-64. Adjuvant formulations with IDR peptides have shown promise 24 
in various preclinical studies for vaccines against mycoplasma63, influenza HINI strain239, and 25 
pertussis240. In these studies, IDR peptides with modest antimicrobial activity used in different vaccine 26 
formulations showed profound immunomodulatory effects. For example, a bactenecin derived-IDR 27 
peptide used in a vaccine formulation with M. bovis proteins elicited a balanced humoral IgG1/IgG2 28 
response for use in cattle63. Intranasal administration of a nanoparticle-based vaccine formulation 29 
containing an immunomodulatory IDR peptide as an adjuvant resulted in a strong cellular and humoral 30 
response against H1N1 influenza strain239. The potential use of IDR peptide as an adjuvant in vaccines 31 
is strongly supported by studies demonstrating that the presence of IDR peptide in these formulations is 32 
22 
 
effective in eliciting a balanced Th1/Th2 immune response along with facilitating the reduction of 1 
antigen dose required for immunity241.  2 
The application of immunomodulatory CHDP in wound healing is also being explored, driven by 3 
studies showing that growth factors associated with stimulation of regeneration of tissues also induce 4 
the production of endogenous CHDP such as LL-37, β-defenisn and lipocalin in keratinocytes242. 5 
Aligned with this, in vitro studies have demonstrated that CHDP such as defensins and LL-37 promote 6 
angiogenesis and wound healing243-246, prevent protease-mediated skin barrier damage247 and promote 7 
re-epithelialisation of wounds248. These phenotypic changes are driven by peptide-mediated activation 8 
of signaling intermediates and transcription factors that activate EGFR through the induction of a G-9 
protein-coupled receptor, in particular for the peptide LL-37244. Accordingly, application of LL-37 was 10 
shown to be effective in a murine model of excisional wound244.  11 
 12 
[H3] Clinical trials  13 
Despite many preclinical studies describing the immunomodulatory therapeutic potential of CHDP-14 
derived peptides, there have been very few successful clinical trials. The human cathelicidin LL-37 has 15 
been applied in a first-in-man randomized, placebo-controlled clinical trial, and shown to be both safe 16 
with no local or systemic adverse reactions and to enhance healing of hard-to-heal venous leg ulcers 17 
(Table II)224. A recent notable study in current clinical development is the use of silicone hydrogel 18 
contact lenses coated with a synthetic immunomodulatory peptide Mel4 to reduce contact lens-19 
associated infections and inflammation249. Notably, the potential therapeutic and prophylactic success 20 
of immunomodulatory CHDP-derived peptides as alternatives to antibiotics in veterinary medicine may 21 
pave the way for clinical trials in humans (One Health approach)250.  22 
  23 
[H1] Considerations in CHDP-based drug development 24 
The use of natural CHDP as effective therapeutics is not particularly viable as concentrations that 25 
exhibit direct antimicrobial effects are relatively high, and at that concentration range these peptides 26 
exhibit cytotoxic effects such as mast cell degranulation, complement activation and apoptosis of 27 
mammalian cells, and induce pro-inflammatory cytokine production11,12,15,251 . Thus, synthetic peptides 28 
derived from natural CHDP, synthetic designed peptides and peptides found by semi-random high 29 
throughput screening are now emerging as putative lead compounds. Recent studies have also focused 30 
on non-peptide CHDP mimics such as peptoid analogs and developing compounds using CHDP on 31 
small abiotic scaffolds, for therapeutic applications (reviewed in24).  32 
23 
 
Major challenges facing peptide-based drug development include formulation and delivery, as well 1 
as high production cost. Biological factors that affect peptide stability and bioavailability must be taken 2 
into consideration, for example mucosal pH and the presence of host or microbial proteases that can 3 
degrade candidate peptides252-254, as well as several other factors which can impair peptide activity such 4 
as physiological salt concentration, mucus, DNA and microbial saccharides252,254. Several approaches 5 
are therefore being explored to enhance peptide stability, such as using D-amino acid peptides and 6 
modification of peptides by amidation or acetylation of the terminal regions or by targeted substitutions 7 
of tryptophan or histidine with a non-natural amino acid (reviewed in212).  8 
The antimicrobial activity of CHDP is generally less than that of conventional antibiotics. 9 
Regulatory authorities require new antimicrobials to be non-inferior to existing antibiotics, even if the 10 
new compounds do not elicit antimicrobial resistance. CHDP may be unsuitable for standard in vitro 11 
antimicrobial susceptibility test methodologies to predict in vivo efficacy, even for topical application, 12 
and more physiologically relevant modified approaches may be vital255. Taking all this into 13 
consideration, the oral or systemic use of CHDP, with the aim to directly kill microorganisms, will 14 
likely be difficult to achieve. However, discoveries of CHDP demonstrating effects against antibiotic 15 
resistant pathogens do hold promise217, as does the new direction of applying immunomodulatory 16 
CHDP as an adjunct to antibiotics, due to the observed synergy of CHDP with conventional 17 
antibiotics256-259.  18 
Additional approaches that are being considered to counter the challenges associated with CHDP-19 
based therapy include the use of nutritional supplements such as vitamin D or phenylbutyrate or other 20 
products based on short chain fatty acids to enhance the levels of endogenous CHDP226. In addition, 21 
topical application of analogs of vitamin D was shown to enhance local expression of cathelicidin in 22 
psoriatic skin, which would circumvent any challenges that may be related to high systemic levels of 23 
vitamin D260,261. Also formulations using nanoparticles or liposomes for slow release and targeted 24 
delivery of CHDP262-264, as well as the use of shorter synthetic peptides such as IDR or cryptic peptides 25 
are being examined (discussed above). In preclinical studies56-59, shorter synthetic peptides such as IDR 26 
peptides have demonstrated negligible toxicity, no immunogenicity, and cost considerably less to 27 
produce than most CHDP, thus making these valuable candidates to investigate for clinical application. 28 
In addition, considerable less peptide is required if CHDP are used as immunomodulatory agents 29 
compared to their use as direct antimicrobial agents. Furthermore, new production methods such as the 30 




Although CHDP offer a promising approach to treat infections, a key challenge for the use of CHDP 1 
or related synthetic analogues as antimicrobials is the development of pathogen-associated resistance 2 
mechanisms. Indeed resistance of pathogens to human CHDP has been demonstrated with multiple 3 
mechanisms adapted by bacteria to evade the direct antimicrobial effects of the peptides267-269 (see Box. 4 
1 and Fig. 4). However, bacteria have a limited number of ways to resist CHDP, and this resistance is 5 
often costly. An important recent study of in vivo survival and pathogenicity of a CHDP-resistant S. 6 
aureus (evolved in vitro in the presence of cationic peptides) showed that resistance to the peptides 7 
provided no survival advantage to the bacteria in an insect host environment that is dominated by 8 
antimicrobial peptides, bacterial clearance was at least as efficient as for the sensitive strains270. 9 
Nevertheless, harnessing the immunomodulatory actions of CHDP to selectively boost the host 10 
immune response rather than directly targeting the pathogen may be the path forward in the 11 
development of CHDP-based anti-infective therapies. 12 
 13 
[H1] Outlook  14 
The repertoire of functions exhibited by CHDP ranges from direct antimicrobial activity to a wide 15 
range of effects on host defense mechanisms, highlighting the critical role of these molecules in 16 
infection and immunity. Although, research in this field was initially focused on the development of 17 
new ‘antibiotics’ based on cationic antimicrobial peptides, it is now well appreciated that CHDP have a 18 
critical role in immunity; from activation of innate immunity, enhancement of antigen presentation and 19 
phagocytosis, to influencing adaptive immunity and memory functions, along with potent anti-20 
inflammatory functions. It is thus not surprising that research in this field has intensified in the context 21 
of drug development for a variety of clinical applications ranging from the control of antibiotic-22 
resistant pathogens, alleviation of inflammation in chronic disease, their use as antibiotic adjuvants, to 23 
the targeting of specific cancers. However, there are many challenges associated with CHDP-based 24 
drug development, notably those associated with formulation and delivery, the potential for drug 25 
resistance, as well as the lack of solid pharmacokinetic data. Nevertheless, the wide range of CHDP 26 
functions defined to date provides a diverse range of natural molecules for the design and optimization 27 
of new drugs. Despite many associated challenges and the limited understanding of structure-function 28 
relationships, the potential of CHDP-based therapies remains a promising new clinical direction.  29 
Boxes 30 
Box 1: Development of antimicrobial resistance to CHDP:  31 
25 
 
A major consideration for the potential application of CHDP as new generation antibiotics will have to 1 
include a thorough understanding of the frequency of resistance development of pathogens to peptide-2 
based therapies. CHDP have promise over small molecule antibiotics because the surfaces with which 3 
they interact with targets in the pathogen are larger271 and hence single amino acid substitutions are 4 
unlikely to lead to adaptations of bacteria to mitigate CHDP activity. Furthermore, CHDP have 5 
complicated mechanisms of action, often interacting with more than one target in microbes, such that 6 
multiple mutations within the pathogen are needed for ‘resistance’ to the peptides. Indeed, a recent 7 
study showed that bacterial adaptations to resist CHDP action do not develop easily272. The additional, 8 
indirect CHDP-mediated effects of enhancing host immune responses to control infections provide an 9 
important complementation to the direct microbicidal activities, providing a multi-faceted attack on 10 
pathogens during infection. Nevertheless, recent studies have revealed that bacterial and fungal 11 
pathogens are capable of developing mechanisms to resist the effects of CHDP. The mechanisms of 12 
adaptation of pathogens to human CHDP have been studied extensively and reviewed267-269.  Common 13 
mechanisms in bacteria to counter the effects of CHDP are repulsion, sequestration, removal and 14 
degradation (Fig. 4). Additional mechanisms of bacterial adaptations are modification of the 15 
pentapeptide on Lipid II, a prominent CHDP target, and by altering the rigidity of the membrane by 16 
acylation of Lipid A.  Mechanisms that fungi employ to enhance tolerance to CHDP have mainly 17 
focused on Candida species, which also employ repulsion, sequestration, removal by efflux pumps and 18 
proteolytic degradation against peptides such as LL-37, histatin 5, HNP-1, hBD-3 and lactoferrin273. 19 
Commensal bacteria of the host microbiome must be able to survive the CHDP presented by epithelial 20 
and mucosal surfaces. This may in part be due to the relatively low concentrations of CHDP at mucosal 21 
surfaces (except for specific niches such as the intestinal crypts) and somewhat inhibitory environments 22 
in which secreted CHDP are present normally in the absence of inflammation. In addition, proteases 23 
that cleave endogenous peptides to generate the active form of mature CHDP are also either absent or 24 
inactive in the absence of an inflammatory response. In contrast, CHDP in the phagolysosome of a 25 
neutrophil, for example, are at a high concentration in a controlled environment optimized for pathogen 26 
killing.  Relative bacterial resistance to host CHDP is a prerequisite for effective commensal 27 
colonisation131, a property which may be most critical for stability through periods of inflammation 28 
where increased levels of CHDP may be capable of preferentially removing pathogens without totally 29 
decimating the healthy microbiome. Harnessing this sort of selectivity would have clear therapeutic 30 
advantages over broad spectrum antibiotics, and is indeed the focus of an exciting new approach to 31 





Figure 1: Structures of CHDP  3 
Part a illustrates examples of structures of CHDP from vertebrates. Two cathelicidins are depicted: 4 
human LL-37 and chicken CATH-2 (with proline-induced kink). Two human defensins are shown: the 5 
α-defensin HD-5 and the β-defensin HBD-2. The pairing and positioning of the six conserved cysteine 6 
residues is as follows: α-defensins: Cys1-Cys6, Cys2-Cys4, Cys3-Cys5; β-defensins: Cys1-Cys5, 7 
Cys2-Cys4, Cys3-Cys6. Magainin-2, a peptide from Xenopus laevis; its analogue, pexiganan, was 8 
developed as a topical agent. Amino acid side chains: red, hydrophobic; blue, basic; green, acidic. Part 9 
b provides examples of the diversity of CHDP structures. Tertiary structures of selected peptides from 10 
plants, fungi and invertebrates, arranged by secondary structure content. Beta strands shown in blue, 11 
alpha helices in red, and disulphide bonds in yellow (PDBs: 1MR4, 1NB1, 2RNG, 1BHP, 1GD3, 12 
2L2R, 1JBL, 1HEV, 2MAL, 5E5Q, 5OQS). 13 
 14 
Figure 2: Models of antibacterial mechanisms of CHDP. Direct antimicrobial mechanisms of CHDP 15 
can be mediated by membrane translocation of the peptides followed by binding to intracellular targets 16 
such as nucleic acids and/or proteins to kill bacteria. The mechanisms of translocation are not clear and 17 
may depend on the peptide and bacterial species. Proline-rich antimicrobial peptides use inner 18 
membrane transporters as Trojan horses to gain entry and subsequently bind within the ribosomal exit 19 
tunnel. Other CHDP may use transient pores for translocation. Interaction of CHDP with negatively 20 
charged bacterial membrane resulting in membrane perturbation has been defined as a primary mode of 21 
direct antimicrobial action. The models of membrane perturbation proposed are barrel-stave, carpet and 22 
toroidal pore models.  The barrel-stave model was the first permeabilization mechanism proposed and 23 
considered to be the prototype in peptide-mediated transmembrane pore formation. In this model, 24 
peptides act as staves and vertically insert into the lipid bilayer forming barrels. Peptides which act 25 
according to the carpet model cover the negatively charged membrane based on electrostatic attraction. 26 
Above a certain peptide threshold concentration, the membrane ruptures in a detergent-like manner 27 
resulting in micelle formation of peptide with membrane lipids. The toroidal model is a variation of the 28 
aggregate model, where after parallel binding of the peptide to the membrane, the peptide distorts the 29 
alignment of the polar head groups of the lipids. This results in perturbation of the acyl chain 30 
interactions of the lipids, changes in membrane curvature and destabilization of membrane surface 31 
27 
 
integrity. At certain peptide to lipid ratios, the peptides orient perpendicularly to the membrane and 1 
induce the formation of transient toroidal channels. 2 
 3 
Figure 3: Summary of immunomodulatory mechanisms of CHDP. Immunomodulatory functions 4 
exhibited by CHDPs include but are not limited to; recruitment of antigen presenting cells to site of 5 
infections either directly or indirectly by induction of chemokines to enhance antimicrobial effects, 6 
facilitating the activation of NETs, altering endotoxin-mediated signaling pathways, suppression of 7 
pro-inflammatory cytokines, enhancing phagocytosis and pro-inflammatory responses to nucleic acids, 8 
induction of anti-inflammatory cytokines, influencing differentiation of dendritic cell and polarization 9 
of T-cells. Adapted from van der Does A, Hiemstra P and Mookherjee N, Adv Exp Med Biol  201915. 10 
 11 
Figure 4: Diagram of common resistance mechanisms to CHDP in bacterial and fungal 12 
pathogens. (A) Gram positive bacteria (B) Gram negative bacteria (C) yeast/fungi. 1. Degradation by 13 
secreted proteases, outer membrane proteases or cytosolic proteases. 2. Sequestration by secreted 14 
proteins, anionic polysaccharides, mannosylphosphate side chains on glycoproteins (fungi) or O-15 
antigen (Gram negative bacteria). 3. Electrostatic repulsion by alanylated lipoteichoic acid (LTA) or 16 
wall teichoic acid (WTA). 4. Electrostatic repulsion by aminoacylated phospatidyl glycerol (PG). 5. 17 
Blocking CHDP binding by altering the pentapeptide on Lipid II. 6. Export of CHDP by efflux pumps. 18 
7. Activation of signal transduction pathways that induce expression of genes that reinforce the wall or 19 
detoxify products of CHDP activity. 8. Lipid A modification by amine compounds. 9. Enhanced 20 
membrane rigidity by lipid A acylation. 10. Activation of MAPK signaling pathways in fungi for 21 
protection against oxidative, osmotic or cell wall stress. Adapted from Joo et al., 2016, and Swidergall 22 







Table I: Antiviral activities of cationic host defence antimicrobial peptides 2 
Virus Peptide Proposed mechanism of action in vitro  References 
Influenza HNP  Virus aggregation 
 Inhibition of PKC disrupts IAV 
endosomal trafficking 





 Retrocyclins  Virus aggregation 
 Increased virus uptake by professional 
phagocytes 
 RC2: haemagglutinin-mediated fusion 




 β-defensins  Inhibition of IAV infectivity at higher 





 LL-37  Disruption of viral envelope 116,218,277 




    
RSV hBD2  Viral envelope destabilisation in 
solution or upon exposure to plasma 
membrane-associated hBD2 
88,278  
 LL-37  Virion binding and destruction  
 Prevention of infection and spread 




    
Rhinovirus Cathelicidins  Decreased infectivity and replication 91,95 
   
Adenovirus α-defensins  Peptide binding to adenoviral capsid 
prevents uncoating and nuclear entry of 
the viral genome 






   








 HSV binding to cellular receptors 
glycoprotein B and heparin sulphate 
inhibited 


















    
HIV HNP  Disruption of cellular entry  
 Inhibition of PKC activity, interfering 
with HIV replication 
106,280-282 
  
 Retrocyclins  Viral entry into cells blocked by 
peptide binding to gp120 and CD4 
 Dependent upon lectin-like properties 
107-110,283-285 
 
 β-defensins  Direct effects on virions 





 LL-37  Suppression of HIV reverse 
transcriptase activity 
289,290  
    
Vaccinia virus Cathelicidins  Integrity of the double layered viral 
envelope damaged
92,291  
    
Zika virus Cathelicidins  Direct inactivation of Zika virus 
 Protective modulation of interferon 
signalling pathways
93  





  Disruption of viral envelope 292  
30 
 















Analog of magainin, 
isolated from African 











































Phase III complete Mallinckrodt NCT00608959 
Papulopustular 
rosacea 






























































amino acid peptide 































Histatin 5 derivative 
(12 amino acids) 





Sold over the counter 




LL-37 Human cathelicidin 
subunit 

















Ulcerative proctitis / 
ulcerative 
proctosigmoiditis 
Phase II complete. 
Phase III planned
Alfasigma S.p.A Not listed 
Oral mucositis in 
patients with head 




















Lytix Biopharma NCT01223222,  
2010-021438-68 
Impetigo Phase II 
complete 
Lytix Biopharma NCT01803035 





























Phase II complete OctoPlus BV/Dr 




C16G2 Synthetic peptide Prevention of dental 
caries due to 
Streptococcus 
mutans 









DPK 060 Derived from 
kininogen, cationic 
random coil peptide 








Atopic dermatitis Phase I/II 
complete 















PL-5 Alpha helical peptide Bacterial skin 
infections 
Approval by State 
Food and Drug 
Administration of 










analog of daptamycin 
















Oral mucositis in 
patients with head 
















Ulcerative colitis Phase II complete Genzyme/Procter & 
Gamble 
2004-004077-29 










































Oral mucositis in 
patients with 
head and neck 
cancer 
Phase III 
current.   









based on the 
cationic 
antimicrobial 
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Candidaemia Phase I/II 
withdrawn
AM-Pharma NCT00509834 






Friulimicin B Cyclic lipopeptide Pneumonia, 
Staphylococcal 
skin infections 
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Expression of cell wall biosynthesis,
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